Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12609-014-0152-1 http://scihub22266oqcxt.onion/10.1007/s12609-014-0152-1 C4235783!4235783!25419441     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Breast+Cancer+Rep 2014 ; 6 (3): 154-8 Nephropedia Template TP {{tp|p=25419441|t=2014. Molecular Heterogeneity of Triple Negative Breast Cancer |pdf=|usr=}}{{25419441}} gab.com Text Molecular Heterogeneity of Triple Negative Breast Cancer JO: Curr Breast Cancer Rep http://www.kidney.de/pget.php?&tw=1&pmid=25419441 #FOAvip Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes. Twit Text FOAVip Molecular Heterogeneity of Triple Negative Breast Cancer ????Curr Breast Cancer Rep http://www.kidney.de/pget.php?&tw=1&pmid=25419441 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25419441 #FOAvip English Wikipedia <ref>{{Cite pmid|25419441}}</ref> Molecular Heterogeneity of Triple Negative Breast Cancer #MMPMID25419441 Abramson VG; Mayer IA Curr Breast Cancer Rep 2014[Sep]; 6 (3): 154-8 PMID25419441show ga Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes. äMolecular Heterogeneity of Triple Negative Breast Cancer (epmc).pdf DeepDyve Pubget Overpricing